Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.76 Million SEK | 114.03% |
| 2022 | -20.24 Million SEK | -925.6% |
| 2021 | 2.59 Million SEK | 166.04% |
| 2020 | -1.58 Million SEK | 74.93% |
| 2019 | -14.98 Million SEK | 37.62% |
| 2018 | -23.96 Million SEK | -31.68% |
| 2017 | -18.13 Million SEK | -211.6% |
| 2016 | -5.81 Million SEK | -1918.56% |
| 2015 | 319.64 Thousand SEK | 11.89% |
| 2014 | 286 Thousand SEK | -91.31% |
| 2013 | 3.29 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.37 Million SEK | -424.19% |
| 2023 Q2 | 6.99 Million SEK | 388.22% |
| 2023 FY | - SEK | 114.03% |
| 2023 Q1 | -2.42 Million SEK | 71.55% |
| 2023 Q4 | -1.26 Million SEK | -119.04% |
| 2023 Q3 | 6.64 Million SEK | -5.0% |
| 2022 Q2 | 1.16 Million SEK | 67.15% |
| 2022 Q1 | 694 Thousand SEK | 591.61% |
| 2022 FY | - SEK | -925.6% |
| 2022 Q4 | -8.53 Million SEK | 37.62% |
| 2022 Q3 | -13.68 Million SEK | -1279.31% |
| 2021 Q2 | 55 Thousand SEK | -96.14% |
| 2021 Q1 | 1.42 Million SEK | 150.26% |
| 2021 FY | - SEK | 166.04% |
| 2021 Q4 | -141.17 Thousand SEK | -115.69% |
| 2021 Q3 | 900 Thousand SEK | 1536.36% |
| 2020 Q3 | 1.6 Million SEK | -52.44% |
| 2020 FY | - SEK | 74.93% |
| 2020 Q4 | -2.83 Million SEK | -277.19% |
| 2020 Q2 | 3.36 Million SEK | 214.76% |
| 2020 Q1 | -2.93 Million SEK | 31.37% |
| 2019 Q4 | -4.27 Million SEK | -15.6% |
| 2019 FY | - SEK | 37.62% |
| 2019 Q1 | -4.67 Million SEK | 44.31% |
| 2019 Q2 | -2.25 Million SEK | 51.8% |
| 2019 Q3 | -3.69 Million SEK | -64.2% |
| 2018 FY | - SEK | -31.68% |
| 2018 Q4 | -8.38 Million SEK | -1.16% |
| 2018 Q3 | -8.29 Million SEK | -381.44% |
| 2018 Q2 | -1.72 Million SEK | 68.53% |
| 2018 Q1 | -5.47 Million SEK | 19.57% |
| 2017 Q1 | -1.06 Million SEK | 82.52% |
| 2017 FY | - SEK | -211.6% |
| 2017 Q4 | -6.8 Million SEK | 11.93% |
| 2017 Q3 | -7.72 Million SEK | -204.95% |
| 2017 Q2 | -2.53 Million SEK | -137.21% |
| 2016 Q3 | -1.48 Million SEK | 23.51% |
| 2016 Q1 | 3.7 Million SEK | 888.39% |
| 2016 FY | - SEK | -1918.56% |
| 2016 Q2 | -1.93 Million SEK | -152.2% |
| 2016 Q4 | -6.11 Million SEK | -312.86% |
| 2015 Q4 | 375 Thousand SEK | 144.67% |
| 2015 Q3 | -839.52 Thousand SEK | 0.0% |
| 2015 FY | - SEK | 11.89% |
| 2014 FY | - SEK | -91.31% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 111.361% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 97.873% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 97.873% |
| Arcoma AB | 6.24 Million SEK | -40.229% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 109.737% |
| BICO Group AB (publ) | 322.3 Million SEK | 97.282% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 86.721% |
| CellaVision AB (publ) | 207.24 Million SEK | 95.772% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 112.808% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 131.355% |
| C-Rad AB (publ) | 48.9 Million SEK | 82.084% |
| Duearity AB (publ) | -24.77 Million SEK | 135.359% |
| Dignitana AB (publ) | -264 Thousand SEK | 3418.761% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 109.99% |
| Getinge AB (publ) | 5.92 Billion SEK | 99.852% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 113.028% |
| Iconovo AB (publ) | -35.33 Million SEK | 124.795% |
| Luxbright AB (publ) | -23.86 Million SEK | 136.71% |
| Mentice AB (publ) | 28.87 Million SEK | 69.655% |
| OssDsign AB (publ) | -122.02 Million SEK | 107.18% |
| Paxman AB (publ) | 31.22 Million SEK | 71.944% |
| Promimic AB (publ) | -3.68 Million SEK | 337.827% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 105.821% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 116.905% |
| ScandiDos AB (publ) | -13.35 Million SEK | 165.6% |
| Sectra AB (publ) | 615.06 Million SEK | 98.576% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 116.955% |
| Senzime AB (publ) | -118.82 Million SEK | 107.374% |
| SpectraCure AB (publ) | -20.96 Million SEK | 141.783% |
| Stille AB | 56.04 Million SEK | 84.366% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 100.275% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 93.078% |